Eli Lilly and Company
Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies
Last updated:
Abstract:
The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors in combination with anti-human PD-1 antibodies, chemotherapy, and ionizing radiation.
Status:
Grant
Type:
Utility
Filling date:
4 Dec 2017
Issue date:
7 Jun 2022